Exploring Zepbound® (tirzepatide) Injection with a Clinical Expert

Overview

Join us on Friday, April 10th from 12:10 - 12:55 PM in Industry Theater 5, Room 201, Level 2 to explore the clinical evidence behind Zepbound® (tirzepatide) injection. This session will address efficacy, safety, and dosing considerations while also offering practical guidance on identifying appropriate adult patients for your practice.

This program is sponsored by, and presented on behalf of, Lilly USA, LLC. It is being presented consistently with FDA guidelines and is not approved for continuing education credit.

Please see Full Prescribing Information including Boxed Warning and Medication Guide at the product theater or on https://zepbound.lilly.com.

Zepbound® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Program Objectives
- Participants completing this program will gain knowledge in the following areas:
- Key efficacy and safety findings from clinical data
- Criteria for identifying appropriate adult patients
- Dosing and administration instructions